 Shares of Pliant Therapeutics Inc. PLRX, 2.62 soared about 75 in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients received the 320 milligram dose the highest dose and will continue to receive treatment for 24 weeks. 